Pfizer’s Wall Street critic-turned-executive digs into the company’s problems, obesity plans

What's new in pharma

March 21, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Brooke Alexander for STAT STAT+ | Pfizer's Wall Street critic-turned-executive digs into the company's problems, obesity plans Andrew Baum, a one-time critic of the company, talked Thursday about Pfizer's drug development, including its obesity drug danuglipron. By Allison DeAngelis STAT+ | Alnylam drug wins FDA approval for progressive heart disease The FDA cleared Alnylam's therapy for the heart disease ATTR-CM, setting the company up to compete with drugs from BridgeBio and Pfizer. By Elaine Chen 'We're living in the Twilight Zone': Researchers decry Trump administration assault on science At the STAT Summit on Thursday, researchers called for a "full-throated defense" of university research against attacks by the Trump administration. By Usha Lee McFarling Alex Hogan/STAT STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser